

Special Issue

Marine Natural Products with Anticoagulant Activity 2022

Message from the Guest Editor

Thrombosis is the formation of blood clots in blood vessels, limiting normal blood flow. It leads to serious complications if clots get dislodged and move to crucial parts of the circulatory system, and remains a major reason for mortality worldwide. Anticoagulants, also referred to as "blood thinners", inhibit various factors of coagulation pathways, and are one of the two main classes of antithrombotic therapy. With the remaining drawbacks of the prevailing anticoagulant therapies, novel alternative therapeutic anticoagulant treatments with promising properties have been gaining increasing attention and clinical concerns. The bioactive marine sources have gained significant attention for the development of anticoagulant drugs due to their structural diversity, unique mechanism of action, and numerous inherent health benefits. With this Special Issue, we will provide a specialized platform for researchers to publish original research and review articles highlighting the applications of products derived from marine sources, as well as modified marine-derived products, in novel anticoagulant drugs.

Guest Editor

Prof. Dr. Won-Kyo Jung

Biomedical Engineering, Marine-Integrated Bionics R&D Center,
Fisheries-Integrated Biomedical Materials R&D Center, College of
Engineering, Pukyong National University, Busan 608-737, Republic of
Korea

Deadline for manuscript submissions

closed (15 December 2022)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/104236

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))